ArticleAging cell2025
Comprehensive evaluation of lifespan-extending molecules in C. elegans.
Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- Egg Peptides From American Shad Extend Lifespan and Healthspan in Caenorhabditis elegans via Lipid Metabolism Remodeling and Antioxidant Defense.Chemistry & biodiversity · 2026Article
- Article
- Vitamin K2 Extends Lifespan by Alleviating Mitochondrial Stress via the JNK-1/SIR-2.1/DAF-16 Signaling Axis in Caenorhabditis elegans.Aging cell · 2026Article
- Elucidating the toxicity of the plasticizer DPhP: Evidence of neurotoxicity and developmental impairment fromCurrent research in toxicology · 2026Article
- Cyrene: a novel geroprotective compound that extends lifespan and healthspan in C. elegans and Drosophila.npj aging · 2025Article
- Distribution Analysis of the Lifespan Trait in Drosophila.International journal of molecular sciences · 2025Article
- Tardigrade Dsup extendsScience advances · 2025Article
- An mTOR inhibitor discovery system using drug-sensitized yeast.GeroScience · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nematode C. elegans has long served as a gold-standard model organism in aging research, particularly since the discovery of long-lived mutants in conserved aging pathways including daf-2 (IGF1) and age-1 (PI3K). Its short lifespan and small size make it highly suitable for high-throughput experiments. While numerous molecules have been tested for their effects on C. elegans lifespan, consensus is still lacking regarding the most effective and reproducible compounds. Confounding effects, especially those related to drug-bacteria interactions, remain a contentious issue in the literature. In this study, we evaluated 16 of the most frequently reported lifespan-extending molecules in C. elegans, examining their effects on lifespan with two different diets (live and UV-killed OP50). In addition, we assessed the compounds' impact on bacterial growth, their effects on various nematode strains, and the impact of the starting age of treatment. Our findings first confirmed robust lifespan extension by many, but not all, of the 16 tested compounds from the literature, and revealed that some of them could be combined to obtain additive effects. Additionally, we showed that some of these compounds also extend lifespan in the fly D. melanogaster, demonstrating a conserved effect across species. Finally, by expanding our screen to a broader pool of molecules, we identified novel lifespan-extending compounds in C. elegans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.